A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
The main objectives of this study are to determine the feasibility and safety of AU-011 treatment of bladder cancer utilizing intratumoral injection with or without intramural injection and with or without laser application.
Non-muscle-invasive Bladder Cancer|Muscle-Invasive Bladder Carcinoma
DRUG: AU-011|COMBINATION_PRODUCT: AU-011 in Combination with Medical Laser Adminstration|COMBINATION_PRODUCT: AU-011 in Combination with Medical Laser Administration
Safety of AU-011: Incidences of SAEs and DLTs, Incidence and severity of treatment-related adverse events and serious adverse events (SAEs) and incidence of dose-limiting toxicities (DLTs)., 56 days
Aura is conducting a Phase 1, 'window of opportunity', open-label trial of belzupacap sarotalocan (AU-011) to determine the feasibility and safety of intratumoral injection with or without intramural injection and with or without laser application in subjects with bladder cancer.